Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company Deals

Yaguo Technology Secures Series A+ Funding for Airway Management Devices

Fineline Cube Nov 4, 2022

Yaguo Technology Co., Ltd, an airway management and respiratory therapy device maker based in Beijing,...

Company Deals

Novatim Immune Therapeutics Raises RMB 500M in First Financing Round

Fineline Cube Nov 4, 2022

China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...

Company Deals

Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round

Fineline Cube Nov 4, 2022

Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised...

Company Drug

Akeso Biopharma Completes Enrollment for AK112 Phase III Study

Fineline Cube Nov 4, 2022

China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...

Company Drug

Eccogene Gains FDA Approval for Phase I Study of ECC5004

Fineline Cube Nov 3, 2022

Shanghai-based Eccogene has announced receiving approval from the US FDA to initiate a Phase I...

Company Drug

BeiGene’s Brukinsa Receives EU Marketing Approval for Marginal Zone Lymphoma

Fineline Cube Nov 3, 2022

China-based biotech BeiGene Inc. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced receiving marketing approval from...

Company Deals

Dartsbio Licenses Potential First-in-Class BsAb DS005 to Duality Biologics

Fineline Cube Nov 3, 2022

China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality...

Company Deals

Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical

Fineline Cube Nov 3, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of...

Company Drug

Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA

Fineline Cube Nov 3, 2022

China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...

Company Medical Device

Sino Medical Sciences’ Non-Compliant Balloon Catheter Approved by NMPA

Fineline Cube Nov 3, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving market approval from the...

Company Drug

Hengrui’s Pyrotinib Granted Breakthrough Therapy Designation by CDE

Fineline Cube Nov 3, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Hengrui Medicine Co., Ltd’s (SHA:...

Company Drug

NMPA Approves Humanwell’s Generic Clobazam for Lennox-Gastaut Syndrome

Fineline Cube Nov 3, 2022

China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version (oral suspension) of Sanofi’s clobazam (trade name:...

Company Drug

NMPA Approves Luye Pharma’s LY03005 for Depression Treatment

Fineline Cube Nov 3, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that its Category 1 chemical drug LY03005...

Company Drug Policy / Regulatory

Shanghai SMPA Suspends HEC’s Linagliptin Procurement Over Patent Infringement

Fineline Cube Nov 3, 2022

The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has revealed that it has suspended the...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Clearance for Sublingual Rasagiline

Fineline Cube Nov 3, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced receiving clinical clearance from the National Medical...

Company Deals

Baidu Health Partners with Shanghai Epiprobe for Cancer Early Screening

Fineline Cube Nov 3, 2022

China Internet giant Baidu’s Health Internet Hospital unit has announced a partnership with Shanghai Epiprobe...

Company Deals

Pharmaniaga Partners with JD.com to Enter China Market

Fineline Cube Nov 3, 2022

Malaysia-based pharma company Pharmaniaga Berhad (Pharmaniaga) is planning to bring its products into mainland China...

Company Drug

Eli Lilly’s Peresolimab and LOXO-783 Gain Tacit Clinical Trial Approvals in China

Fineline Cube Nov 2, 2022

The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...

Company Drug

Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China

Fineline Cube Nov 2, 2022

China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...

Company Medical Device

Yiming and Hexaell’s HepaCure Biocolumn Receives IND Approval for HBV-Induced Liver Failure

Fineline Cube Nov 2, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...

Posts pagination

1 … 550 551 552 … 609

Recent updates

  • WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
  • NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
  • AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
  • Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
  • WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.